|
|
AH:CpG |
|
Vaxjo ID |
243 |
|
Vaccine Adjuvant Name |
AH:CpG |
|
Alternative Names |
Aluminum Hydroxide + CpG Oligodeoxynucleotide (TLR9 agonist) |
|
Adjuvant VO ID |
VO_0005521
|
|
Description |
A combination adjuvant pairing aluminum hydroxide (AH) with CpG (TLR9 agonist) to enhance Th1-polarized immunity and antibody production against SARS-CoV-2 |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
Alum and CpG enhance SARS-CoV-2 RBD protective immunity |
|
Structure |
A physical mixture of aluminum hydroxide gel (Alhydrogel) and synthetic CpG-ODNs (e.g., CpG-1018, CpG-2395) |
|
Appearance |
Formulated by mixing recombinant SARS-CoV-2 RBD protein with AH and CpG prior to injection |
|
Storage |
Suitable for ambient storage and lyophilization |
|
Dosage |
In mice: CpG: 50 µg (CpG-1018 or CpG-2395) AH: 100 µg RBD antigen: 10 µg per dose (i.m. injection) |
|
Function |
Alum and CpG enhance SARS-CoV-2 RBD protective immunity, variant neutralization in aged mice and Th1-polarizing cytokine production by human elder leukocytes. |
|
Safety |
Demonstrated good safety in preclinical models and human PBMCs; no significant adverse effects observed |
| References |
Nanishi et al., 2021: Nanishi E, Borriello F, O'Meara TR, McGrath ME, Saito Y, Haupt RE, Seo HS, van Haren SD, Brook B, Chen J, Diray-Arce J, Doss-Gollin S, Leon M, Chew K, Menon M, Song K, Xu AZ, Caradonna TM, Feldman J, Hauser BM, Schmidt AG, Sherman AC, Baden LR, Ernst RK, Dillen C, Weston SM, Johnson RM, Hammond HL, Mayer R, Burke A, Bottazzi ME, Hotez PJ, Strych U, Chang A, Yu J, Barouch DH, Dhe-Paganon S, Zanoni I, Ozonoff A, Frieman MB, Levy O, Dowling DJ. Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity. bioRxiv : the preprint server for biology. 2021; ; . [PubMed: 34031655].
|
|
